Employing epigenetic protein degradation techniques to block CCL5-mediated photodynamic therapy via a programmed...

Area of Science:

• Oncology
• Nanotechnology
• Epigenetics

Background:

• Photodynamic therapy (PDT) shows promise for cancer treatment but faces challenges like poor photosensitizer accumulation and epigenetic-regulated resistance.
• Epigenetic modifications play a role in cancer progression and therapeutic resistance, necessitating targeted interventions.

Purpose of the Study:

• To develop a novel tumor microenvironment-responsive delivery platform for co-delivering epigenetic protein degraders and photosensitizers.
• To enhance the efficacy of combination therapy by overcoming PDT resistance and improving tumor targeting.

Main Methods:

• Development of a pH-triggered, glutathione (GSH)-responsive nanodelivery platform.
• Co-delivery of epigenetic protein degraders and photosensitizers.
• Evaluation of tumor accumulation, therapeutic effects, and immune modulation in preclinical cancer models (breast cancer, melanoma).

Main Results:

• The delivery platform demonstrated enhanced tumor accumulation and therapeutic efficacy due to its targeting, pH-triggered charge reversal, and GSH-responsive release.
• The combination therapy inhibited tumor immune escape molecules (PD-L1, CD47) and M2 macrophage polarization.
• Photodynamic therapy-induced resistance via CCL5 upregulation was identified and shown to be reducible by BRD4 degradation.

Conclusions:

• Integrating PDT with epigenetic protein degraders via a programmed delivery platform offers a promising strategy to improve cancer treatment outcomes.
• The developed platform effectively targets tumors, enhances combination therapy, and overcomes resistance mechanisms in preclinical models.
• This study highlights a novel approach to cancer therapy by addressing both direct tumor cell killing and immune evasion pathways.